MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 sept. 2024 16h05 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Pricing of Initial Public Offering
12 sept. 2024 19h11 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Launch of Initial Public Offering
09 sept. 2024 06h30 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
12 août 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
05 août 2024 08h00 HE
|
MBX Biosciences, Inc.
Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2...
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
25 juin 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
05 févr. 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
31 janv. 2024 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
20 déc. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
15 nov. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...